Stock PHN PHARMANUTRA S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Pharmanutra S.p.A.

Equities

PHN

IT0005274094

Pharmaceuticals

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-04-30 am EDT 		5-day change 1st Jan Change
53.4 EUR -.--% Intraday chart for Pharmanutra S.p.A. +1.33% -5.32%
Apr. 22 Lists in green except Mib; banks good AN
Apr. 22 Iveco down on Mib; European stock exchanges in green AN

Business Summary

Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Number of employees: 105

Sales per Business

EUR in Million2022Weight2023Weight Delta
Direct
63.4 %
57 69.5 % 64 63.4 % +10.56%
Indirect
31.5 %
23 28.1 % 32 31.5 % +35.83%
Akern
5.0 %
2 2.4 % 5 5.0 % +156.50%

Sales per region

EUR in Million2022Weight2023Weight Delta
Italy
67.8 %
59 71.6 % 68 67.8 % +14.76%
Europe
16.9 %
13 15.7 % 17 16.9 % +29.77%
Middle East
10.6 %
8 9.5 % 11 10.6 % +35.44%
South America
1.9 %
-- 2 1.9 % -
Far East
1.5 %
1 1.0 % 2 1.5 % +84.09%
Others
1.2 %
1 1.0 % 1 1.2 % +53.24%

Managers

Managers TitleAgeSince
Andrea Lacorte CEO
 Chief Executive Officer - 02-12-31
Germano Tarantino CTO
 Chief Tech/Sci/R&D Officer - -
Carlo Volpi COO
 Chief Operating Officer - 08-12-31
Via Delle Lenze IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Giovanna Zanotti BRD
 Director/Board Member 52 20-08-31
Andrea Lacorte CEO
 Chief Executive Officer - 02-12-31
Carlo Volpi COO
 Chief Operating Officer - 08-12-31
Germano Tarantino CTO
 Chief Tech/Sci/R&D Officer - -
Roberto Lacorte FOU
 Founder - -
Alessandro Calzolari BRD
 Director/Board Member - -
Marida Zaffaroni BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 9,680,977 3,323,436 ( 34.33 %) 65,985 ( 0.6816 %) 34.33 %

Shareholders

NameEquities%Valuation
Andrea Lacorte
31.38 %
3,038,334 31.38 % 187 M €
Roberto Lacorte
23.13 %
2,238,833 23.13 % 138 M €
Carlo Volpi
10.48 %
1,014,993 10.48 % 62 M €
Norges Bank Investment Management
3.456 %
334,575 3.456 % 21 M €
Germano Tarantino
1.872 %
181,250 1.872 % 11 M €
Danske Bank A/S (Investment Management)
1.740 %
168,480 1.740 % 10 M €
Joh. Berenberg, Gossler & Co. KG (Investment Management)
1.737 %
168,201 1.737 % 10 M €
Kairos Partners SGR SpA
1.710 %
165,529 1.710 % 10 M €
Crédit Mutuel Asset Management SA
1.033 %
100,000 1.033 % 6 M €
Arca Fondi SGR SpA
0.9417 %
91,169 0.9417 % 6 M €

Holdings

NameEquities%Valuation
PHARMANUTRA S.P.A.
0.68%
 65,381 0.68% 4,024,854 $

Company contact information

Pharmanutra SpA

Via Campodavela 1

56122, Pisa

+39 05 07 84 65 00

https://www.pharmanutra.it/it/
address Pharmanutra S.p.A.(PHN)

Group companies

NameCategory and Sector
Akern

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Pharmanutra S.p.A.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
53.4 EUR
Average target price
80.67 EUR
Spread / Average Target
+51.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMANUTRA S.P.A. Stock Pharmanutra S.p.A.
-5.32% 549M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHN Stock
  4. Company Pharmanutra S.p.A.